Literature DB >> 23148170

Review of therapeutic advances in diabetic retinopathy.

Chirag P Shah1, Carolyn Chen.   

Abstract

Diabetic retinopathy is a common microvascular complication of prolonged diabetes. It is one of the leading causes of vision loss in working age adults and a significant source of morbidity. To reduce the incidence and severity of diabetic retinopathy, it is important to identify patients at risk and promptly implement intensive glycemic and hypertensive control. To date, there are many interventions that can limit moderate and severe vision loss in people with diabetes, including laser photocoagulation, vitrectomy surgery, and intravitreal pharmacological injections. This review aims to define the different stages of diabetic retinopathy and the important therapeutic advances developed to address the major causes of vision loss in each stage.

Entities:  

Keywords:  bevacizumab; diabetic macular edema; diabetic retinopathy; proliferative diabetic retinopathy; vision loss; vitrectomy

Year:  2011        PMID: 23148170      PMCID: PMC3474624          DOI: 10.1177/2042018810396750

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  80 in total

1.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

Authors:  Prema Abraham; Huibin Yue; Laura Wilson
Journal:  Am J Ophthalmol       Date:  2010-07-03       Impact factor: 5.258

2.  Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis.

Authors:  M Egger; G Davey Smith; C Stettler; P Diem
Journal:  Diabet Med       Date:  1997-11       Impact factor: 4.359

3.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

4.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

5.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

6.  Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.

Authors:  Yusuke Oshima; Chiharu Shima; Taku Wakabayashi; Shunji Kusaka; Fumio Shiraga; Masahito Ohji; Yasuo Tano
Journal:  Ophthalmology       Date:  2009-03-09       Impact factor: 12.079

7.  Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane.

Authors:  J W Harbour; W E Smiddy; H W Flynn; P E Rubsamen
Journal:  Am J Ophthalmol       Date:  1996-04       Impact factor: 5.258

8.  Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

Authors:  Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan
Journal:  Arch Ophthalmol       Date:  2008-12

Review 9.  Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy.

Authors:  Marta S Figueroa; Inés Contreras; Susana Noval
Journal:  Curr Diabetes Rev       Date:  2009-02

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  5 in total

1.  Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.

Authors:  Y Sun; D Wang; F Ye; D-N Hu; X Liu; L Zhang; L Gao; E Song; D Y Zhang
Journal:  Eye (Lond)       Date:  2013-08-09       Impact factor: 3.775

2.  Fangchinoline Ameliorates Diabetic Retinopathy by Inhibiting Receptor for Advanced Glycation End-Products (RAGE)-Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Pathway in Streptozotocin (STZ)-Induced Diabetic Rats.

Authors:  Qi Wu; Haojie Liu; Ming Zhou
Journal:  Med Sci Monit       Date:  2019-02-11

Review 3.  Role of Choline in Ocular Diseases.

Authors:  Jin-Sun Hwang; Young-Joo Shin
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Fibroblast Growth Factor Type 1 Ameliorates High-Glucose-Induced Oxidative Stress and Neuroinflammation in Retinal Pigment Epithelial Cells and a Streptozotocin-Induced Diabetic Rat Model.

Authors:  Hsin-Wei Huang; Chung-May Yang; Chang-Hao Yang
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

5.  Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.

Authors:  Kun Liu; Hanying Wang; Wei He; Jian Ye; Yanping Song; Yusheng Wang; Xiaoling Liu; Zhifeng Wu; Shaojun Chen; Ke Fan; Yuling Liu; Feng Zhang; Zhiqing Li; Lin Liu; Junjun Zhang; Xuedong Zhang; Junjie Ye; Xiaoling Liang; Xiaoxin Li; Xiao Ke; Quan Wu; Jie Li; Shanshan Tao; Xinguo Wang; Philip Rosenfeld; Jeffrey S Heier; Peter Kaiser; Xun Xu
Journal:  Br J Ophthalmol       Date:  2021-05-17       Impact factor: 5.908

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.